Direxion Daily S&P Biotech Bull 3X Shares (LABU)
$170.88
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Key data on LABU
AUM
$585176168
P/E ratio
17.3
Dividend yield
0.8069%
Expense ratio
0.93%
Beta
2.567316
Price on LABU
Previous close
$163.19
Today's open
$165.35
Day's range
$164.75 - $176.59
52 week range
$32.55 - $198.18
Popular funds like LABU
LABU industries and sectors
Equities
Multi Alternative
News on LABU
Triple-Leveraged Biotech ETF Doubles as Regulatory Winds Shift in 2026
Triple-leveraged ETFs aren't for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull 3X Shares (NASDAQ:LABU) offers the most aggressive way to capture that move.
24/7 Wall Street • Jan 16, 2026
Navigate Biotech's Crosscurrents With Direxion's LABU And LABD ETFs
Although the equities market often embodies chaos and capricious non-linearity, few sectors witness as much kinetic wildness like biotechnology. At its core, biotech represents an innovative push toward addressing the human condition — which is often found to be shockingly frail.
Benzinga • Dec 18, 2025
Top Performing Leveraged/Inverse ETFs: 11/16/2025
Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
ETF Trends • Nov 19, 2025
New FDA Director Could Sway Biotech ETFs
Biotech stocks could sway toward the upside with the appointment of a new director at the Federal Drug Administration's Center for Drug Evaluation and Research. Dr. Richard Pazdur will take the reigns, bringing 26 years of related industry experience.
ETF Trends • Nov 14, 2025
Investing In Health Stocks - How Policy Clarity Is Opening Doors
The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.
Seeking Alpha • Nov 11, 2025
As M&A Deals Rise, Can Biotech Pharma Break Loose?
After a relatively sluggish 2024 for mergers & acquisitions (M&A) activity in the biopharma sector, the environment could be more conducive for deals in the rest of 2025. The industry, like the rest of the capital markets, will be keeping an eye on interest rates as monetary easing by the U.S.
ETF Trends • Sep 19, 2025
Top Performing Leveraged/Inverse ETFs: 09/07/2025
Top Performing Levered/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
ETF Trends • Sep 9, 2025
Top Performing Leveraged/Inverse ETFs: 08/17/2025
Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
ETF Trends • Aug 19, 2025
Healthcare Sector Checkup As U.S. Looks To Change Regulations
Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.
Seeking Alpha • May 30, 2025
Top Performing Leveraged/Inverse ETFs: 04/20/2025
Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
ETF Trends • Apr 22, 2025
¹ Disclosures
Invest in Direxion Daily S&P Biotech Bull 3X Shares
Open an M1 investment account to buy and sell Direxion Daily S&P Biotech Bull 3X Shares commission-free¹. Build wealth for the long term using automated trading and transfers.